Differentiating rectal carcinoma by an immunohistological analysis of carcinomas of pelvic organs based on the NCBI Literature Survey and the Human Protein Atlas database
- 23 March 2012
- journal article
- review article
- Published by Springer Nature in Surgery Today
- Vol. 42 (6) , 515-525
Abstract
The treatments and prognoses of pelvic organ carcinomas differ, depending on whether the primary tumor originated in the rectum, urinary bladder, prostate, ovary, or uterus; therefore, it is essential to diagnose pathologically the primary origin and stages of these tumors. To establish the panels of immunohistochemical markers for differential diagnosis, we reviewed 91 of the NCBI articles on these topics and found that the results correlated closely with those of the public protein database, the Human Protein Atlas. The results revealed the panels of immunohistochemical markers for the differential diagnosis of rectal adenocarcinoma, in which [+] designates positivity in rectal adenocarcinoma and [−] designates negativity in rectal adenocarcinoma: from bladder adenocarcinoma, CDX2[+], VIL1[+], KRT7[−], THBD[−] and UPK3A[−]; from prostate adenocarcinoma, CDX2[+], VIL1[+], CEACAM5[+], KLK3(PSA)[−], ACPP(PAP)[−] and SLC45A3(prostein)[−]; and from ovarian mucinous adenocarcinoma, CEACAM5[+], VIL1[+], CDX2[+], KRT7[−] and MUC5AC[−]. The panels of markers distinguishing ovarian serous adenocarcinoma, cervical carcinoma, and endometrial adenocarcinoma were also represented. Such a comprehensive review on the differential diagnosis of carcinomas of pelvic organs has not been reported before. Thus, much information has been accumulated in public databases to provide an invaluable resource for clinicians and researchers.Keywords
This publication has 122 references indexed in Scilit:
- Endoluminal metastasis of colon cancer to the urinary bladder via the ureter: Report of a caseSurgery Today, 2010
- Current Status of Prognostic Immunohistochemical Markers for Urothelial Bladder CancerTumor Biology, 2008
- High‐grade ovarian serous carcinoma exhibits significantly higher p16 expression than low‐grade serous carcinoma and serous borderline tumourHistopathology, 2007
- Diagnosis of adenocarcinoma in prostate needle biopsy tissueJournal of Clinical Pathology, 2007
- Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 casesLaboratory Investigation, 2006
- MUC1, MUC2, MUC4, MUC5AC and MUC6 Expression in the Progression of Prostate CancerClinical & Experimental Metastasis, 2005
- Differential Expression of MUC1, MUC2, and MUC5AC in Carcinomas of Various Sites An Immunohistochemical StudyAmerican Journal of Clinical Pathology, 2004
- Histological classification of ovarian cancerMedical Molecular Morphology, 2003
- Immunophenotypic Characterization of 225 Prostate Adenocarcinomas With Intermediate or High Gleason ScoresAmerican Journal of Clinical Pathology, 2002
- Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion moleculeCell, 1989